Spago Nanomedical AB

All marketplaces will be closed on December 24, 25, 26, and 31, as well as on January 1, 2026, due to public holidays

Spago Nanomedical conducts research and development in cancer diagnostics. The company conducts various development projects based on its proprietary nanomaterials whose potential is found in making tumours visible, and enabling internal radiation therapy of cancer. The company was founded in 2007 and is based in Lund.

Quotes for Spago Nanomedical AB

Right Now

+/-
%
Latest
High
Low
Volume
Turnover ()
Time (Latest trade)

Board

CEO

  • Mats Hansen

Chairperson of the Board

  • Eugen Steiner

Board

  • Kari Grønås
  • Nicklas Westerholm
  • Peter Leander
  • Sten Nilsson
  • Articles of association

    • News

    Show More

    Analysis

    Videos

    Bolagsintroduktion Spago Nanomedical

    Bolagsintroduktion Direkt: Spago Nanomedical

    In The Spotlight

    Spago sitdown

    Largest Owners

    Name Capital % Votes % Date
    Peter Lindell 45,40 45,40 2025-09-26
    Mikael Lönn 9,19 9,19 2025-09-26
    Eva Redhe 5,28 5,28 2025-06-30
    Tiel Ridderstad 3,87 3,87 2025-06-30
    Nordnet Pensionsförsäkring 2,41 2,41 2025-09-26
    Avanza Pension 1,40 1,40 2025-09-26
    Filippa Lindström 1,39 1,39 2025-09-26
    Futur Pension 1,01 1,01 2025-09-26
    Philip Löchen 0,98 0,98 2025-09-26
    Thord Wilkne 0,93 0,93 2025-09-26

    Annual reports, prospectus etc.